ENESTKorea is a phase 4, multi-institutional, single-arm, open-label study investigating the
efficacy and safety of nilotinib at the currently approved dose (300 mg twice daily) and its
exposure-outcome relationship, in adult patients diagnosed as Philadelphia
chromosome-positive chronic myeloid leukemia in chronic phase.